A new antibody conjugate system that enables highly specific cancer cell killing by direct contact to the cell surface and laser-mediated activation at the tumor site
Photoimmunotherapy was developed by Dr. H. Kobayashi and Dr. P. L. Choyke, the scientific heads of the Molecular Imaging Program at the National Cancer Institute (NCI) and described in Nature Medicine (1).
- Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Nat Med. 2011 Nov 6; 17 (12): 1685-91.
Video Describing the Technology
Photoimmunotherapy (PIT) is based on three components:
- An antibody that binds cancer surface antigens for tumor selective targeting.
- The IRDye700DX molecule is conjugated to the antibody with stable linkers.
- Laser-activation of the antibody conjugate bound to the cancer cells induces specific and rapid killing of only cancer cells sparing dabame to sorrounding tissue.
The combination of cancer targeting with antibody binding to surface antigens and localized laser actyivation of the conjugate permits highly effective cancer ablation while preserving organ function.